Get the latest tech news
Trump’s FDA Cuts Are Putting Drug Development at Risk
New SEC filings from pharmaceutical companies reveal Donald Trump and Elon Musk's cost-cutting measures could slow drug research and delay FDA approvals.
“The Trump Administration has enacted several executive actions that could impose significant burdens on, or otherwise materially delay, the FDA's ability to engage in routine regulatory and oversight activities,” says one filing from Xenon Pharmaceuticals, a company based in Canada that researches treatments for epilepsy. In February, Elon Musk’s so-called Department of Government Efficiency laid off hundreds of FDA employees, causing widespread panic about the status of grant applications, active clinical trials, and drug approvals. iBio, a company based out of San Diego, which studies antibody treatments for obesity and cardio-metabolic disorders, said in a filing that it’s currently “unclear” how Trump’s health care policy will affect grant funding for research in their field.
Or read this on Wired
